Oddo maintains its 'outperform' rating on MedinCell shares, with its target price raised from 11 to 14 euros.

With the FDA expected back in the next few weeks (Q2 2023), the approval followed by the commercial launch of Uzedy (mdc-MRI) are the main catalysts for the stock in the short term, according to the research firm.

For Oddo, this endorsement will mark MedinCell's transition from an R&D biotech to a commercial company, but will also give added credibility to its BEPO platform for obtaining new partnerships.

Finally, in addition to the approval of Uzedy, MedinCells' newsflow over the coming months should be marked by the clinical progress of its two other assets, mdcCWM (celecoxib) for the management of post-operative pain and mdcTJK (olanzapine) in schizophrenia.

We expect Phase III results in late 2023 and Q3/Q4 2024 respectively", concludes the analyst.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.